|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.99 USD | +0.04% |
|
+1.78% | +27.34% |
| Dec. 03 | Pacira Biosciences reports inducement grants under Nasdaq Listing Rule | RE |
| Dec. 02 | Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | $30.17 | +25.75% | 6 | ||||||
| $1,056.7 | +4.59% | 27 | ||||||
| $203.42 | +0.74% | 24 | ||||||
| $243.55 | +7.73% | 29 | ||||||
| CHF 311.78 | +0.28% | 18 | ||||||
| GBX 197.15 | +8.87% | 19 | ||||||
| CHF 131.65 | -1% | 19 | ||||||
| $106.62 | +6.92% | 26 | ||||||
| DKK 398.34 | +28.66% | 20 | ||||||
| $324.25 | -1.71% | 27 | ||||||
| $130.63 | +7.77% | 25 | ||||||
| $29.04 | +11.56% | 24 | ||||||
| €106.13 | +24.86% | 22 | ||||||
| $487.28 | +6.98% | 25 | ||||||
| $53.41 | +2.41% | 22 | ||||||
| GBX 18.33 | +1.55% | 18 | ||||||
| ¥8,553.57 | +3.89% | 14 | ||||||
| $492.17 | +7.43% | 24 | ||||||
| CN¥81.04 | +31.51% | 18 | ||||||
| Average | 681.85 | +9.41% | 21 | ||||||
| Weighted average by Cap. | 564.65 | +6.42% | 24 |
- Stock Market
- Equities
- PCRX Stock
- Sector Pacira BioSciences, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
